# A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

> **NCT07677267** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 1067 (estimated)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07677267
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 1067 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677267, "A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07677267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*